Targeting BAP1: a new paradigm for mesothelioma.


New treatment strategies for malignant pleural mesothelioma (MPM) are important. BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment. Multiple functions of BAP1 are investigated in the preclinical situation. Due to many functions of BAP1, the phenotypic effect of BAP1 is diverse. Preclinical data on inhibitors reversing these phenotypic effects are promising. However, the mechanism of BAP1 is not fully elucidated yet and further research about the mechanism and possible inhibitors is necessary.

More about this publication

Lung cancer (Amsterdam, Netherlands)
  • Volume 109
  • Pages 145-146
  • Publication date 01-07-2017

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.